Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
The DCBLD2 gene, also known as Dedicator of cytokinesis 2, is a cytoplasmic protein that is highly expressed in various tissues and cells, including fibroblasts, epithelial cells, and endothelial cells. The protein is encoded by the DCBLD2 gene, which is located on human chromosome 10q23.1. The gene consists of 10 exons and encodes a protein of 461 amino acids. DCBLD2 is a relatively newly discovered gene that has piqued the interest of researchers due to its potential role in various cellular processes and its implications in human health and disease.
DCBLD2 (Discoidin, CUB and LCCL domain-containing 2) is a gene that encodes a protein possessing Discoidin, CUB, and LCCL domains. These domains are characterized by their distinct structural features and functional roles in various cellular processes. The Discoidin domain, present in the N-terminal region of DCBLD2, is responsible for the protein's interaction with extracellular matrices and cell surfaces. This domain is evolutionarily conserved and is found in many proteins involved in cell adhesion, migration, and signaling. The CUB (CUB-like) domain, located in the central region of DCBLD2, is an immunoglobulin-like domain that mediates protein-protein interactions. This domain is involved in cell signaling, protein trafficking, and cell attachment. In DCBLD2, the CUB domain interacts with other cellular components, contributing to the overall function of the protein.The LCCL (Laminin, Collagen, and Fibronectin-like) domain, located in the C-terminal region of DCBLD2, shares similarity with laminin, collagen, and fibronectin. This domain is involved in cell signaling, cell adhesion, and extracellular matrix organization. It interacts with various cellular components and plays a crucial role in regulating cell behavior and tissue structure. Together, the Discoidin, CUB, and LCCL domains of DCBLD2 contribute to the overall structural and functional complexity of the protein.
DCBLD2 gene has been implicated in cardiovascular disease pathogenesis, playing a pivotal role in several cellular processes that contribute to the development and progression of cardiovascular conditions. DCBLD2 interacts with components of the extracellular matrix (ECM), influencing cell signaling, adhesion, and migration. Abnormalities in these processes can lead to inappropriate cell proliferation, inflammation, and fibrosis - key factors associated with cardiovascular disease.
In the context of atherosclerosis, DCBLD2 has been found to regulate the expression of genes involved in macrophage recruitment, lipid metabolism, and plaque stability. Increased expression of DCBLD2 has been linked to enhanced macrophage migration and foam cell formation, promoting atherosclerotic plaque development. Moreover, studies have demonstrated that DCBLD2 is involved in the pathogenesis of hypertensive heart disease. Inhibition of DCBLD2 expression attenuates cardiomyocyte hypertrophy and fibrosis, suggesting that DCBLD2 may represent a potential therapeutic target for hypertensive heart disease.In addition, DCBLD2 has been implicated in remodeling and fibrosis processes following myocardial infarction. The Discoidin and LCCL domains of DCBLD2 interact with ECM components, influencing fibroblast activation and collagen deposition. This contributes to the formation of fibrotic scar tissue, which can lead to diastolic dysfunction and limit heart failure progression.
Overall, the role of DCBLD2 in cardiovascular disease pathogenesis highlights the importance of understanding the complex interactions between genetic factors, cell signaling, and ECM regulation in the development and progression of cardiovascular conditions.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.